| Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release G Kong, G Anyarambhatla, WP Petros, RD Braun, OM Colvin, D Needham, ... Cancer research 60 (24), 6950-6957, 2000 | 651 | 2000 |
| High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer WP Peters, M Ross, JJ Vredenburgh, B Meisenberg, LB Marks, E Winer, ... Journal of Clinical Oncology 11 (6), 1132-1143, 1993 | 643 | 1993 |
| A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with … A Dowlati, K Robertson, M Cooney, WP Petros, M Stratford, J Jesberger, ... Cancer research 62 (12), 3408-3416, 2002 | 504 | 2002 |
| Irinotecan therapy in adults with recurrent or progressive malignant glioma HS Friedman, WP Petros, AH Friedman, LJ Schaaf, T Kerby, J Lawyer, ... Journal of Clinical Oncology 17 (5), 1516-1516, 1999 | 418 | 1999 |
| Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer MS Anscher, WP Peters, H Reisenbichler, WP Petros, RL Jirtle New England Journal of Medicine 328 (22), 1592-1598, 1993 | 401 | 1993 |
| Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow JP Stevenson, M Rosen, W Sun, M Gallagher, DG Haller, D Vaughn, ... Journal of Clinical Oncology 21 (23), 4428-4438, 2003 | 347 | 2003 |
| Three-dimensional hierarchical plasmonic nano-architecture enhanced surface-enhanced Raman scattering immunosensor for cancer biomarker detection in blood plasma M Li, SK Cushing, J Zhang, S Suri, R Evans, WP Petros, LF Gibson, D Ma, ... ACS nano 7 (6), 4967-4976, 2013 | 286 | 2013 |
| Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors ML Hauck, SM LaRue, WP Petros, JM Poulson, D Yu, I Spasojevic, ... Clinical Cancer Research 12 (13), 4004-4010, 2006 | 199 | 2006 |
| Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion GM Beasley, RP Petersen, J Yoo, N McMahon, T Aloia, W Petros, ... Annals of surgical oncology 15, 2195-2205, 2008 | 155 | 2008 |
| Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer WP Petros, PJ Hopkins, S Spruill, G Broadwater, JJ Vredenburgh, ... J Clin Oncol 23 (25), 6117-6125, 2005 | 143 | 2005 |
| Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer SW Wilczynski, JJ Erasmus, WP Petros, JJ Vredenburgh, RJ Folz American journal of respiratory and critical care medicine 157 (2), 565-573, 1998 | 142 | 1998 |
| Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects MV Relling, J Cherrie, MJ Schell, WP Petros, WH Meyer, WE Evans Clinical Pharmacology & Therapeutics 50 (3), 308-313, 1991 | 134 | 1991 |
| Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin‐oxidation and N‐acetylation phenotypes in children WE Evans, MV Relling, WP Petros, WH Meyer, J Mirro Jr, WR Crom Clinical Pharmacology & Therapeutics 45 (5), 568-573, 1989 | 121 | 1989 |
| Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support J Rabinowitz, WP Petros, AR Stuart, WP Peters | 102 | 1993 |
| Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support KS BHALLA, SW WILCZYNSKI, AM ABUSHAMAA, WP PETROS, ... American journal of respiratory and critical care medicine 161 (1), 17-25, 2000 | 99 | 2000 |
| Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel MC Cox, J Low, J Lee, J Walshe, N Denduluri, A Berman, MG Permenter, ... Clinical cancer research 12 (15), 4636-4640, 2006 | 95 | 2006 |
| Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. WL Furman, DL Fairclough, RD Huhn, CB Pratt, N Stute, WP Petros, ... Journal of clinical oncology 9 (6), 1022-1028, 1991 | 90 | 1991 |
| Effects of tobacco smoking and nicotine on cancer treatment WP Petros, IR Younis, JN Ford, SA Weed Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32 (10 …, 2012 | 87 | 2012 |
| A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer AJ Armstrong, P Creel, J Turnbull, C Moore, TA Jaffe, S Haley, W Petros, ... Clinical Cancer Research 14 (19), 6270-6276, 2008 | 81 | 2008 |
| Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer CJ Gilbert, WP Petros, J Vredenburgh, A Hussein, M Ross, P Rubin, ... Cancer chemotherapy and pharmacology 42, 497-503, 1998 | 81 | 1998 |
